Indivior reports a 108% profit surge, driven by strong sales of its opioid use disorder treatment Sublocade.
Indivior Pharmaceuticals (INDV) posted a 108% year-over-year profit increase, fueled by rising demand for its opioid use disorder (OUD) treatment, Sublocade. The Virginia-based company focuses on advancing therapies for OUD amid a persistent U.S. opioid crisis.
The surge follows strong revenue growth and expanded institutional ownership, with Indivior’s relative strength line hitting new highs. Analysts highlight the company’s positioning in a high-need market as a key driver of performance.
Shares of Indivior have gained momentum, reflecting investor confidence in its long-term growth prospects tied to addiction treatment demand.